Floatz logo

Therapeutic Asset Ratings

329 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Inv-347
Obesity Disorder
Novo Nordisk A/SP1C (36)
ly3971297
Obesity Disorder
Eli Lilly and CompanyP1C (36)
ly41747794
Obesity Disorder
Eli Lilly and CompanyP1C (36)
Mbx 4291
Obesity Disorder
MBX BiosciencesP1C (36)
nnc0113-5840
Obesity Disorder
Novo Nordisk A/SP1C (36)
nnc0174-1213 a
Obesity Disorder
Novo Nordisk A/SP1C (36)
nnc0638-0355
Obesity Disorder
Novo Nordisk A/SP1C (36)
pg-102
Obesity Disorder
RANI TherapeuticsP1C (36)
RT-114
Obesity Disorder
RANI TherapeuticsP1C (36)
Shr-2906
Obesity Disorder
Beijing Suncadia Pharmaceuticals Co., LtdP1C (36)
Tlc-6740
Obesity Disorder
OrsoBio, IncP1C (36)
Voriconazole
Obesity
OrsoBio, IncP1C (36)
Vrb-103
Obesity Disorder
Verdiva Bio Dev LimitedP1C (36)
Xen-101
Obesity Disorder
Xeno BiosciencesP1C (36)
Carbon Dioxide
Obesity Disorder
University of Missouri-ColumbiaEarly P1C (36)
Epinephrine
Obesity
IVO JURISICEarly P1C (36)
NEOMYCIN
Obesity Disorder
Assaf Harofeh MCEarly P1C (36)
Acetazolamide
Obesity Disorder
University of ArizonaEarly P1C (33)
Apple Cider Vinegar
Obesity Disorder
Western UniversityEarly P1C (33)
Gip[3-30]Nh2
Obesity Disorder
Frederikke Koefoed-HansenEarly P1C (33)
Isoproterenol
Obesity Disorder
University of Missouri-ColumbiaEarly P1C (33)
Milk Polar Lipid-Rich Dairy Powder
Obesity Disorder
University of ConnecticutEarly P1C (33)
M-SYMPATHOL
Obesity Disorder
University of Missouri-ColumbiaEarly P1C (33)
NEUROPEPTIDE Y HUMAN
Obesity Disorder
University of Texas Southwestern Medical CenterEarly P1C (33)
Noradrenaline
Obesity Disorder
University of Missouri-ColumbiaEarly P1C (33)
Showing 251 to 275 of 329 assets
PreviousPage 11 of 14Next